OCCL Ltd
OCCLLTDOCCL Ltd is coiled. The quarters are improving, yet the P/E sits at the 5th percentile of its own 1-year range — the business is moving before the market.
Biggest watch item: the price is already 8 weeks into its uptrend — timing risk, not thesis risk.
The price is in a confirmed uptrend (8 weeks in) while the P/E sits at the 5th percentile of its own 1-year range. Underneath, the last four quarters read improving — profit +207.7% year on year, and 117% of the last 2 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
OCCL Ltd trades at ₹166, in a confirmed uptrend and 8 weeks into that stage. That is +48.0% against its own 200-day average. It sits at 100% of a 52-week range of ₹93 to ₹166. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 8 straight weeks.
Today the stock is in a confirmed uptrend — week 8 of stage 2, confirmed. At ₹166 it trades +48.0% versus its 200-day average and sits at 100% of its 52-week range (₹93–₹166).
Against the market, two honest reads. Cumulative: over the last 4 months the stock moved +72% while the NIFTY 500 moved +2% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 8 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
OCCL Ltd trades at 10.9× P/E, near the bottom of its own range — cheaper only 5% of the time. Its long-run median P/E is 13.2×, measured across 1.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 10.9× is near the bottom of its own range — cheaper only 5% of the time, against a long-run median of 13.2× measured over 1.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
OCCL Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 4 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +64.8% | — | — | — |
| Profit | +128.6% | — | — | — |
| EPS | +122.6% | — | — | — |
4-Factor Sector Score
62.1/100 — rank 3 of 20 in Chemicals - Organic · 60% evidence confidence
OCCL Ltd scores 62.1 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 3. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 26.2 + 12.1 + 11.5 + 12.3 = 62.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
OCCL Ltd reported ₹220 Cr of revenue in the Jun 26 quarter, +78.9% year on year. That is the 4th straight quarter of year-on-year growth. The last full year, FY26, came in at ₹506 Cr. The last four reported quarters add to ₹603 Cr.
FY26 revenue came in at ₹506 Cr (+64.8% on the year). The latest quarter (Jun 26) printed ₹220 Cr, +78.9% year on year — the 4th consecutive quarter of year-over-year growth.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
OCCL Ltd's operating margin is 28.0% in the Jun 26 quarter, +7.0 percentage points against the same quarter a year ago.
The latest quarter's operating margin is 28.0%, +7.0 pp against the same quarter a year ago. Across 2 fiscal years the operating margin has ranged 17.0%–18.0%.
Why the margin moved: operating margin went +6.7 pp year on year while gross margin went −3.3 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
OCCL Ltd earned ₹40.0 Cr of net profit in the Jun 26 quarter, +207.7% year on year. It is the 4th consecutive quarter of growth. Full-year FY26 profit was ₹48.0 Cr. That is 18.2% of the quarter's revenue. The same quarter a year earlier earned ₹13.0 Cr.
Jun 26 profit was ₹40.0 Cr, +207.7% year on year — the 4th consecutive quarter of growth. On the full year, FY26 printed ₹48.0 Cr (+128.6%).
Why profit moved: revenue contributed +78.9% and the margin +7.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +92.8% vs revenue +38.4%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 2 fiscal years 117% of OCCL Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹11.0 Cr of operating cash against ₹48.0 Cr of profit. After ₹12.0 Cr of capital spending, ₹−1.0 Cr was left as free cash.
FY26: operating cash of ₹11.0 Cr against reported profit of ₹48.0 Cr, leaving free cash of ₹−1.0 Cr after ₹12.0 Cr of capital spending. Across the last 2 fiscal years the conversion rate is 117% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 117%: the cash cycle tightened 29 days between FY25 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 8.3× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
OCCL Ltd's cash conversion cycle runs 160 days in FY26, down from 189 days in FY25. Capital spending ran ₹415 Cr over the last 3 years. At FY26 sales of ₹506 Cr each day of that cycle holds about ₹1.4 Cr, so roughly ₹222 Cr sits inside the business at any moment.
FY26: debtors at 61 days, inventory at 139 days — roughly 4.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 160 days, tighter than FY25's 189.
The full loop: cash goes out to suppliers and production on day 0; stock waits 139 days to sell; customers pay about 61 days after that; and suppliers themselves are paid at 41 days — netting out to the 160-day cycle.
In money terms: at FY26 sales of ₹506 Cr, each day of the cycle holds about ₹1.4 Cr — so the 160-day loop keeps roughly ₹222 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹415 Cr over the last 3 fiscal years against ₹50.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹2.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
OCCL Ltd earns a ROCE of 13% in FY26. That is up from a trough of −86% in FY24. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 9.5% net margin on 0.84× asset turns.
FY26 ROCE is 13%, recovered from a FY24 trough of −86% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 9.5% net margin × 0.84× asset turns × 1.40× balance-sheet leverage ≈ 11.2% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
OCCL Ltd carries ₹84.0 Cr of borrowings against ₹431 Cr of equity in FY26, a debt-to-equity of 0.19. Operating profit covers the interest bill 18×. Over 3 years borrowings went from ₹0.0 Cr to ₹84.0 Cr. Capital spending ran ₹415 Cr across the last 3 of those years.
FY26: borrowings of ₹84.0 Cr against equity of ₹431 Cr — a debt-to-equity of 0.19. Operating profit covers the interest bill 18×. Over 3 years borrowings went from ₹0.0 Cr to ₹84.0 Cr while capital spending ran ₹415 Cr in just the last 3 — part of the build-out is riding on borrowed money.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of OCCL Ltd moved a full percentage point over the last two years — the register is quiet. Foreign institutions moved −0.7 points over the same window, to 0.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: −0.9 points over 6 quarters to 4.8%; Foreign institutions: −0.7 points over 6 quarters to 0.3%; Promoters: +0.0 points over 6 quarters to 51.8%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
OCCL Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Nitta Gelatin India LtdKERALACHEM | 82.3/100Sector-leading setup78% evidence | 27.8/35 Revenue 11.8% · PAT 34.1% · OPM change 10 pp 83% evidence | 20.2/25 ROCE 31.3% · OPM 28% 76% evidence | 14.3/20 P/E 13.5× · PEG — 50% evidence | 20.0/20 RS sector 71.7% · RS bench 85.7% · 1Y 75.4%4 of 4 weeks ahead to 2026-06-07 100% evidence | |
| Exact sum: 27.8 + 20.2 + 14.3 + 20 = 82.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Balaji Amines LtdBALAMINES | 64.9/100Mixed-positive evidence82% evidence | LEADER | 26.7/35 Revenue 11.1% · PAT 41.6% · OPM change 10 pp 95% evidence | 13.2/25 ROCE 11% · OPM 25% 76% evidence | 6.6/20 P/E 33.9× · PEG — 50% evidence | 18.4/20 RS sector 27.9% · RS bench 45.8% · 1Y 26.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.7 + 13.2 + 6.6 + 18.4 = 64.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3OCCL Ltdthis pageOCCLLTD | 62.1/100Mixed-positive evidence60% evidence | TURNING | 26.2/35 Revenue 40.6% · PAT 100% · OPM change 7 pp 95% evidence | 12.1/25 ROCE 12.8% · OPM 28% 76% evidence | 11.5/20 P/E 10.9× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 46.7% · 1Y —3 of 3 weeks ahead 25% evidence |
| Exact sum: 26.2 + 12.1 + 11.5 + 12.3 = 62.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Shri Ahimsa Naturals LtdSHRIAHIMSA | 60.8/100Thin evidence · provisional56% evidence | LEADER | 18.9/35 Revenue — · PAT — · OPM change -2 pp 26% evidence | 17.8/25 ROCE 21.7% · OPM 28% 95% evidence | 10.3/20 P/E 30.9× · PEG — 15% evidence | 13.8/20 RS sector 22.1% · RS bench 40.5% · 1Y 114.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 17.8 + 10.3 + 13.8 = 60.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Indo Amines LtdINDOAMIN | 59.8/100Mixed-positive evidence77% evidence | TURNING | 22.5/35 Revenue 7.6% · PAT 42.9% · OPM change 2 pp 83% evidence | 16.0/25 ROCE 19.9% · OPM 11% 95% evidence | 13.9/20 P/E 11.7× · PEG — 50% evidence | 7.4/20 RS sector -12.9% · RS bench 0.5% · 1Y -15%10 of 10 weeks ahead 70% evidence |
| Exact sum: 22.5 + 16 + 13.9 + 7.4 = 59.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Foseco India LtdFOSECOIND | 57.4/100Mixed-positive evidence83% evidence | TURNING | 18.6/35 Revenue 26.9% · PAT 7.5% · OPM change 2 pp 88% evidence | 14.9/25 ROCE 17.4% · OPM 20% 100% evidence | 11.1/20 P/E 39.7× · PEG 1.31 65% evidence | 12.8/20 RS sector 22.8% · RS bench -2.4% · 1Y 5.3%4 of 10 weeks ahead 70% evidence |
| Exact sum: 18.6 + 14.9 + 11.1 + 12.8 = 57.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Elantas Beck India LtdELANTAS | 50.5/100Mixed-positive evidence72% evidence | ASLEEP | 17.2/35 Revenue 11.1% · PAT 6.6% · OPM change 0 pp 83% evidence | 17.9/25 ROCE 21.2% · OPM 20% 76% evidence | 7.5/20 P/E 50.9× · PEG — 50% evidence | 7.9/20 RS sector -7.6% · RS bench -2.3% · 1Y -26%1 of 7 weeks ahead 70% evidence |
| Exact sum: 17.2 + 17.9 + 7.5 + 7.9 = 50.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Laxmi Organic Industries LtdLXCHEM | 48.2/100Mixed-negative evidence94% evidence | TURNING | 20.8/35 Revenue 5.5% · PAT 26% · OPM change 7.6 pp 100% evidence | 8.2/25 ROCE 4.7% · OPM 12% 100% evidence | 11.8/20 P/E 39.4× · PEG 1.14 100% evidence | 7.4/20 RS sector -20.5% · RS bench 6.3% · 1Y -13.2%10 of 10 weeks ahead 70% evidence |
| Exact sum: 20.8 + 8.2 + 11.8 + 7.4 = 48.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Valiant Organics LtdVALIANTORG | 46.9/100Mixed-negative evidence83% evidence | ASLEEP | 23.0/35 Revenue 2.6% · PAT 100% · OPM change 2 pp 83% evidence | 9.6/25 ROCE 5.5% · OPM 12% 95% evidence | 11.4/20 P/E 25.7× · PEG — 50% evidence | 2.9/20 RS sector -18.7% · RS bench -6.3% · 1Y -29.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 23 + 9.6 + 11.4 + 2.9 = 46.9 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.7% and the one-year return is -29.3%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 10Shree Ganesh Remedies LtdSGRL | 46.6/100Thin evidence · provisional57% evidence | 11.3/35 Revenue -17.3% · PAT -37.7% · OPM change -4.8 pp 53% evidence | 16.4/25 ROCE 19.2% · OPM 31.9% 57% evidence | 8.9/20 P/E 35.1× · PEG — 50% evidence | 10.0/20 RS sector 2.3% · RS bench -9.9% · 1Y -15.8%4 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 11.3 + 16.4 + 8.9 + 10 = 46.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Fairchem Organics LtdFAIRCHEMOR | 44.4/100Mixed-negative evidence87% evidence | BREAKING OUT | 18.4/35 Revenue 0% · PAT 50% · OPM change 6 pp 95% evidence | 5.7/25 ROCE 3.3% · OPM 10% 95% evidence | 6.0/20 P/E 66.4× · PEG — 50% evidence | 14.3/20 RS sector 1.2% · RS bench 16.6% · 1Y -12.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 5.7 + 6 + 14.3 = 44.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Fine Organic Industries LtdFINEORG | 43.3/100Mixed-negative evidence96% evidence | FADING | 13.8/35 Revenue 4.2% · PAT 1.7% · OPM change 1 pp 88% evidence | 18.0/25 ROCE 21.5% · OPM 21% 100% evidence | 6.0/20 P/E 36.2× · PEG 2.7 100% evidence | 5.5/20 RS sector -10.6% · RS bench 3.4% · 1Y -7.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 18 + 6 + 5.5 = 43.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 13GFL LtdGFLLIMITED | 43.0/100Mixed-negative evidence62% evidence | 20.6/35 Revenue 0% · PAT 100% · OPM change 2562 pp 62% evidence | 6.3/25 ROCE 2.1% · OPM 19% 95% evidence | 11.3/20 P/E 11× · PEG — 15% evidence | 4.8/20 RS sector -14.7% · RS bench -16.8% · 1Y -28.6%1 of 8 weeks ahead 70% evidence | |
| Exact sum: 20.6 + 6.3 + 11.3 + 4.8 = 43 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14BASF India LtdBASF | 40.7/100Mixed-negative evidence90% evidence | ASLEEP | 11.9/35 Revenue -0.4% · PAT -12.5% · OPM change 1.7 pp 88% evidence | 9.3/25 ROCE 14.5% · OPM 3.2% 100% evidence | 12.2/20 P/E 38.1× · PEG 1.62 100% evidence | 7.3/20 RS sector -4.4% · RS bench -8.7% · 1Y -28%1 of 11 weeks ahead 70% evidence |
| Exact sum: 11.9 + 9.3 + 12.2 + 7.3 = 40.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Oriental Aromatics LtdOAL | 38.5/100Mixed-negative evidence74% evidence | TURNING | 13.0/35 Revenue 13.5% · PAT -77.7% · OPM change -0.4 pp 95% evidence | 7.2/25 ROCE 4.5% · OPM 7.6% 95% evidence | 8.7/20 P/E 231× · PEG — 15% evidence | 9.6/20 RS sector -9.8% · RS bench 15.9% · 1Y -3.1%9 of 10 weeks ahead 70% evidence |
| Exact sum: 13 + 7.2 + 8.7 + 9.6 = 38.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Gem Aromatics LtdGEMAROMA | 31.4/100Thin evidence · provisional56% evidence | TURNING | 4.3/35 Revenue -27.3% · PAT -80% · OPM change -8.4 pp 83% evidence | 8.6/25 ROCE 3.4% · OPM 14.2% 95% evidence | 8.5/20 P/E 705× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —2 of 10 weeks ahead 0% evidence |
| Exact sum: 4.3 + 8.6 + 8.5 + 10 = 31.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Sigachi Industries LtdSIGACHI | 25.4/100Adverse evidence77% evidence | TURNING | 6.2/35 Revenue -2.1% · PAT -80% · OPM change -8.8 pp 83% evidence | 6.9/25 ROCE 6.2% · OPM 13.5% 95% evidence | 8.5/20 P/E 30.4× · PEG — 50% evidence | 3.8/20 RS sector -35.5% · RS bench -8.5% · 1Y -33.6%7 of 10 weeks ahead 70% evidence |
| Exact sum: 6.2 + 6.9 + 8.5 + 3.8 = 25.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Sacheerome LtdSACHEEROME | 59.9/100Thin evidence · provisional41% evidence | TURNING | 17.4/35 Revenue — · PAT — · OPM change 1 pp 26% evidence | 20.6/25 ROCE 35.7% · OPM 23% 95% evidence | 10.2/20 P/E 33.3× · PEG — 15% evidence | 11.7/20 RS sector — · RS bench 30.9% · 1Y 141.7%3 of 10 weeks ahead 25% evidence |
| Exact sum: 17.4 + 20.6 + 10.2 + 11.7 = 59.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Jyoti Resins and Adhesives LtdJYOTIRES | 46.1/100Thin evidence · provisional50% evidence | 13.2/35 Revenue 8.7% · PAT -5.5% · OPM change -6 pp 53% evidence | 18.7/25 ROCE 50% · OPM 26% 57% evidence | 10.8/20 P/E 14.3× · PEG — 15% evidence | 3.4/20 RS sector -20.6% · RS bench -30.3% · 1Y -40.3%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 13.2 + 18.7 + 10.8 + 3.4 = 46.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Citurgia Biochemicals LtdCITURGIA | 41.1/100Thin evidence · provisional18% evidence | 14.3/35 Revenue — · PAT -30.4% · OPM change — 18% evidence | 6.8/25 ROCE -2150% · OPM — 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 14.3 + 6.8 + 10 + 10 = 41.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is OCCL Ltd's share price today?
OCCL Ltd trades at ₹166. The company is valued at ₹829 Cr. The stock sits at 100% of its 52-week range of ₹93–₹166, +48.0% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 8 weeks in. — as of 31 July 2026.
What were OCCL Ltd's latest quarterly results?
OCCL Ltd reported revenue of ₹220 Cr and net profit of ₹40.0 Cr for the Jun 26 quarter. Revenue rose 78.9% and profit rose 207.7% year on year. Earnings per share were ₹8.06. The operating margin was 28.0%, 7.0 pp higher than a year earlier. — as of 31 July 2026.
What is OCCL Ltd's revenue?
OCCL Ltd reported revenue of ₹220 Cr in the Jun 26 quarter, +78.9% year on year. For the full FY26 fiscal year, revenue was ₹506 Cr (+64.8%). — as of 31 July 2026.
What is OCCL Ltd's profit?
OCCL Ltd earned ₹40.0 Cr of net profit in the Jun 26 quarter, +207.7% year on year — the 4th straight quarter of growth. Full-year FY26 profit was ₹48.0 Cr. The operating margin ran 28.0% in the latest quarter. — as of 31 July 2026.
What is OCCL Ltd's market cap?
OCCL Ltd's market capitalisation is ₹829 Cr at a share price of ₹166. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is OCCL Ltd's P/E ratio?
OCCL Ltd trades at a P/E of 10.9×, at the 5th percentile of its own 1-year range, against a long-run median of 13.2×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does OCCL Ltd pay a dividend?
Yes — OCCL Ltd's dividend payout was 19% of profit in FY26, and it recorded a payout in 2 of its last 4 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is OCCL Ltd overvalued?
On its own history, OCCL Ltd looks cheap against its own history: its P/E of 10.9× has been cheaper only 5% of the time in 1 years (long-run median 13.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is OCCL Ltd growing?
Yes — OCCL Ltd is growing: latest-quarter revenue +78.9% year on year, profit +207.7%, and the margin +7.0 pp at 28.0%. The earnings engine currently reads: improving — as of 31 July 2026.
How is OCCL Ltd performing?
OCCL Ltd is in a confirmed uptrend, 8 weeks in. Its latest quarter's revenue rose 78.9% and profit rose 207.7% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 8 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
Is OCCL Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 8 of stage 2), trading +48.0% versus its 200-day average and at 100% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is OCCL Ltd beating the market?
On recent form, yes — OCCL Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 8 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 4 months the stock moved +72% against the NIFTY 500's +2% — ahead of the index over the full window. — as of 31 July 2026.
Will OCCL Ltd's share price go up?
This page publishes no price forecast for OCCL Ltd. What it measures instead: the share price is ₹166, the price is in a confirmed uptrend 8 weeks in. Its P/E of 10.9× sits at the 5th percentile of its own 1-year range. — as of 31 July 2026.
Who owns OCCL Ltd?
Promoters hold 51.8% of OCCL Ltd, foreign institutions 0.3%, domestic institutions 4.8% and the public 43.2% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.
Does OCCL Ltd have too much debt?
No — OCCL Ltd's debt-to-equity is 0.19, and operating profit covers the interest bill 18×. FY26 borrowings were ₹84.0 Cr against equity of ₹431 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is OCCL Ltd's capex?
OCCL Ltd spent ₹415 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹12.0 Cr, with ₹2.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is OCCL Ltd's cash flow?
OCCL Ltd generated ₹11.0 Cr of operating cash flow in FY26 and ₹−1.0 Cr of free cash flow after ₹12.0 Cr of capital spending. Reported profit that year was ₹48.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is OCCL Ltd's profit real cash?
Yes — over the last 2 fiscal years, 117% of OCCL Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹11.0 Cr against reported profit of ₹48.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is OCCL Ltd in its business cycle?
OCCL Ltd's FY26 operating margin was 18.0%, against a 2-year band of 17.0%–18.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 28.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the OCCL Ltd story?
Biggest watch item: the price is already 8 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is OCCL Ltd a stock worth studying right now?
This is not investment advice. The machine read: OCCL Ltd is coiled. The quarters are improving, yet the P/E sits at the 5th percentile of its own 1-year range — the business is moving before the market. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.